{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:39:38Z","timestamp":1791214778315,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.clinthera.2012.06.009","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T06:52:39Z","timestamp":1340779959000},"page":"1474-1486","source":"Crossref","is-referenced-by-count":78,"title":["Vemurafenib in Patients With BRAF V600E Mutation\u2013Positive Advanced Melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Marcus C.","family":"Ravnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen S.","family":"Matalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.06.009_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.clinthera.2012.06.009_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1586\/era.11.25","article-title":"Therapy for metastatic melanoma: An overview and update","volume":"11","author":"Boyle","year":"2011","journal-title":"Exp Rev Anticancer Ther"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2012.06.009_bib7","doi-asserted-by":"crossref","first-page":"vii339","DOI":"10.1093\/annonc\/mdq364","article-title":"Advances in systemic treatment of melanoma","volume":"21","author":"Eggermont","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/13543784.2010.527945","article-title":"PLX4032: Does it keep its promise for metastatic melanoma treatment?","volume":"19","author":"Livingstone","year":"2010","journal-title":"Exp Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2012.06.009_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.sder.2010.06.005","article-title":"Targeted molecular therapy in melanoma","volume":"29","author":"Puzanov","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clinthera.2012.06.009_bib10","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","article-title":"The history and future of chemotherapy for melanoma","volume":"23","author":"Yang","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clinthera.2012.06.009_bib12","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib14","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2007.11.9552","article-title":"More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma","volume":"25","author":"McDermott","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1470-2045(12)70005-0","article-title":"A tale of two tumours and a plea for progress","volume":"13","author":"Fisher","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2012.06.009_bib19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.06.009_bib20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1541-7786.MCR-08-0021","article-title":"Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma","volume":"7","author":"Gartside","year":"2009","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib22","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib23","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/PPO.0b013e31823e5357","article-title":"BRAF inhibitors and melanoma","volume":"17","author":"Flaherty","year":"2011","journal-title":"Cancer J"},{"key":"10.1016\/j.clinthera.2012.06.009_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.06.009_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrclinonc.2011.69","article-title":"BRAF targeted therapy changes the treatment paradigm in melanoma","volume":"8","author":"Ribas","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib26","first-page":"906","article-title":"FDA approves vemurafenib for treatment of metastatic melanoma","volume":"25","year":"2011","journal-title":"Oncology (Huntington, NY)"},{"key":"10.1016\/j.clinthera.2012.06.009_bib28","first-page":"77","article-title":"Vemurafenib (zelboraf) for metastatic melanoma","volume":"53","year":"2011","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.clinthera.2012.06.009_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib31","article-title":"BRAF inhibitor gives striking survival advantage in BRIM-3: commentary","volume":"29","author":"Sosman","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clinthera.2012.06.009_bib32","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib33","doi-asserted-by":"crossref","first-page":"14903","DOI":"10.1073\/pnas.1008990107","article-title":"The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner","volume":"107","author":"Joseph","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinthera.2012.06.009_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1755-148X.2010.00763.x","article-title":"PLX4032, a potent inhibitor of the B-raf V600E oncogene, selectively inhibits V600E-positive melanomas","volume":"23","author":"Lee","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib35","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1517\/13543784.2011.542325","article-title":"The natural history of malignancies under conditions of BRAF inhibitor stimulation","volume":"20","author":"White","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2012.06.009_bib40","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.06.009_bib41","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/0008-5472.CAN-11-1875","article-title":"Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation","volume":"72","author":"Su","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.bcp.2010.03.019","article-title":"BRAF as therapeutic target in melanoma","volume":"80","author":"Wellbrock","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4615-3080-0_8","article-title":"Molecular genetics of human malignant melanoma","volume":"65","author":"Albino","year":"1993","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11912-009-0054-y","article-title":"Inside life of melanoma cell signaling, molecular insights, and therapeutic targets","volume":"11","author":"Sosman","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2012.06.009_bib46","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib47","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1755-148X.2010.00779.x","article-title":"Oncogenic RAF: A brief history of time","volume":"23","author":"Solit","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/jid.2011.362","article-title":"MEK'ing the most of p53 reactivation therapy in melanoma","volume":"132","author":"Lee","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib49","first-page":"3660","article-title":"Disruption of the MMAC1\/PTEN gene by deletion or mutation is a frequent event in malignant melanoma","volume":"57","author":"Guldberg","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1523-1747.2000.00877.x","article-title":"Mutation and allelic loss of the PTEN\/MMAC1 gene in primary and metastatic melanoma biopsies","volume":"114","author":"Birck","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2012.06.009_bib52","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1345\/aph.1Q363","article-title":"Vemurafenib (PLX4032): An orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma","volume":"45","author":"Heakal","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"suppl","key":"10.1016\/j.clinthera.2012.06.009_bib54","article-title":"BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib57","first-page":"53","article-title":"Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities","volume":"6","author":"Lemech","year":"2012","journal-title":"Clin Med Insights: Oncology"},{"key":"10.1016\/j.clinthera.2012.06.009_bib58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2011.38.2895","article-title":"Induction of cutaneous squamous cell carcinomas by RAF inhibitors: Cause for concern?","volume":"30","author":"Lacouture","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/edm.11.83","article-title":"A new era for the management of metastatic melanoma","volume":"7","author":"Koneru","year":"2012","journal-title":"Exp Rev Dermatol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib62","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib63","first-page":"1450","article-title":"The authors reply","volume":"365","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib64","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.06.009_bib65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jamcollsurg.2004.10.032","article-title":"Detection of B-RAF and N-RAS mutations in human melanoma","volume":"200","author":"Goydos","year":"2005","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clinthera.2012.06.009_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","article-title":"Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma","volume":"82","author":"Fedorenko","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib67","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFR\u03b2-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib68","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMcibr1013704","article-title":"Resistance to BRAF inhibition in melanomas","volume":"364","author":"Solit","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.06.009_bib69","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2012.06.009_bib70","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.06.009_bib71","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1038\/jid.2010.177","article-title":"The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors","volume":"130","author":"Kaplan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2012.06.009_bib72","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2010.408","article-title":"Hyperactivation of MEK-ERK1\/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells","volume":"30","author":"Kaplan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2012.06.009_bib73","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/pgs.11.166","article-title":"Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas","volume":"13","author":"Lo","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2012.06.009_bib74","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2012.06.009_bib75","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/PPO.0b013e31824b436e","article-title":"Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies","volume":"18","author":"Kudchadkar","year":"2012","journal-title":"Cancer J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T09:20:31Z","timestamp":1542878431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0149291812003724"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}